These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25638865)

  • 1. [Non-invasive follow up of patients with inflammatory bowel diseases].
    Nancey S; Roblin X
    Rev Prat; 2014 Nov; 64(9):1256-61. PubMed ID: 25638865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
    Iijima H; Shinzaki S; Tsujii M; Takehara T
    Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers.
    Schoepfer AM; Vavricka S; Zahnd-Straumann N; Straumann A; Beglinger C
    J Crohns Colitis; 2012 May; 6(4):412-8. PubMed ID: 22398068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fecal calprotectin: a diagnostic tool for inflammatory bowel disease].
    Fraga M; Godat S; Nydegger A; Moradpour D; Schoepfer AM
    Rev Med Suisse; 2012 Sep; 8(352):1669-70, 1672-3. PubMed ID: 22988727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine inflammatory bowel disease: current and prospective biomarkers for diagnosis and management.
    Collins MT
    Compend Contin Educ Vet; 2013 Mar; 35(3):E5. PubMed ID: 23532922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
    Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
    Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: biological activity markers in inflammatory bowel disease.
    Desai D; Faubion WA; Sandborn WJ
    Aliment Pharmacol Ther; 2007 Feb; 25(3):247-55. PubMed ID: 17217454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymes in feces: useful markers of chronic inflammatory bowel disease.
    Angriman I; Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Sturniolo GC; D'Amico DF; Plebani M
    Clin Chim Acta; 2007 May; 381(1):63-8. PubMed ID: 17368600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of fecal biomarkers in inflammatory bowel disease.
    Sutherland AD; Gearry RB; Frizelle FA
    Dis Colon Rectum; 2008 Aug; 51(8):1283-91. PubMed ID: 18543035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Faecal calprotectin in inflammatory bowel diseases: review].
    Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
    Sipponen T
    Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fecal calprotectin in the diagnosis of inflammatory bowel diseases].
    Rodríguez-Moranta F; Lobatón T; Rodríguez-Alonso L; Guardiola J
    Gastroenterol Hepatol; 2013; 36(6):400-6. PubMed ID: 23434080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG
    Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
    Kolho KL; Raivio T; Lindahl H; Savilahti E
    Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of fecal markers of inflammation in inflammatory bowel disease.
    Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.